Recent Advances in Diabetes Therapies in Asia

Asia confronts a disproportionately high diabetes burden, characterized by aggressive pathophysiology and early-onset complications. For addressing this crisis, established therapeutic agents are actively leveraged across Asia via multifaceted approaches, e.g., developing fixed-dose combinations to improve adherence or optimizing drug structures to enhance therapeutic profiles. Concurrently, Asian innovators are advancing emerging target-based agent classes into clinical use, including glucagon-like peptide 1 multiagonists, glucokinase activators, pan-peroxisome proliferator-activated receptor modulators, AMP-activated protein kinase/NOD-like receptor family pyrin domain-containing 3 dual targeted compound, glimins-class oral small molecule, and G-protein-coupled receptor 119 receptor agonist, etc. Technologies such as antisense oligonucleotide (ASO) inhibitors targeting glucagon receptor, stem cell therapy, and microbiome-based glycemic management are also being clinically validated in Asia. Meanwhile, devices such as continuous glucose monitoring, automated insulin delivery systems, and noninvasive glucose monitors are advancing toward broader clinical adoption. This review critically synthesizes Asia's contemporary strategies against diabetes, spanning from the optimization of established target-based agents to the breakthroughs of novel therapeutics and the advancement of maturing technologies and devices. This evolution reflects Asia's accelerating transition from a major clinical trial hub and product consumer to a global driver and leader in innovative glucose-lowering drug development. Propelled by pioneering drug innovators, surging research and development investment, and robust multistakeholder collaboration across industry, academia, and health care, the region is fostering a dynamic innovation ecosystem. Through synergistically advancing the research and application of glucose-lowering therapeutics alongside context-adapted implementation, Asia's practical experience delivers a referable approach for diabetes management across the globe and promotes sustained innovation within diabetology.